Addressing the rate-limiting step in mRNA vaccine screening

WHITE PAPER: Addressing the rate-limiting step in mRNA vaccine screening:

A new paradigm for mRNA synthesis

mRNA as a vaccine platform has demonstrated recent success and promises tremendous potential, but there are still challenges that need to be addressed to realize its full potential. This whitepaper addresses a key challenge in mRNA-based vaccine discovery workflows: mRNA synthesis.

In this whitepaper you will learn:

• How long and inefficient workflows for mRNA synthesis can impact delays in vaccine candidate screening and evaluation.
• Why current mRNA synthesis options are not optimal to realize the full potential of mRNA-based therapeutic vaccine application.
• How using advances in synthetic biology automation can produce synthetic mRNA overnight, promoting vaccine optimization and eliminating weeks of wait time from design to assessment.